Medafen Paediatric is commonly used to provide supportive symptomatic relief across conditions associated with acute or episodic changes in children, focusing on moderating symptoms that interfere with comfort and stability. The therapeutic role of ibuprofen is considered relevant for easing fever and managing minor aches and pain, in situations where patients experience these symptoms.

This medicine is applied across domains where additional symptomatic support is needed, primarily addressing elevated body temperature, mild-to-moderate pain, and localized swelling. The medicine is commonly used in conditions that may include symptomatic manifestations such as headache, toothache, discomfort from teething, symptoms of colds and flu, or pain associated with minor sprains or strains.

Easing Febrile Episodes and High Temperatures

This medicine is generally considered relevant in clinical settings marked by elevated body temperature or fever. It is relevant for easing this pronounced symptom, which may appear suddenly during common childhood illnesses. Its use plays a role in managing fever, which may assist with easing the overall symptom load and contributes to improved comfort during symptomatic phases.

Quick Fact: Relief for Fever This medicine is commonly used when short-term symptomatic assistance is needed to help ease the systemic discomfort and strain related to heightened body temperature.

Regulatory References

1. NIH MedlinePlus Drug Information

Medafen Paediatric (Ibuprofen) is a medicine for infants and children, generally intended for those aged 3 months and over and who weigh at least 5 kg. Official regulatory documents define clear populations who must not use this medicine due to safety risks.

Contraindicated Populations

Population/Condition	Eligibility Status
Allergy to NSAIDs (e.g., Aspirin, Ibuprofen)	Contraindicated (Includes patients with history of asthma, rhinitis, or urticaria following NSAID use)
Active or Recurrent GI Bleeding/Ulceration	Contraindicated (History of perforation or bleeding related to prior NSAID therapy is also prohibited)
Severe Organ Impairment	Contraindicated (Applies to severe heart failure [NYHA Class IV], severe kidney failure, and severe liver dysfunction)
Last Three Months of Pregnancy	Contraindicated
Active Bleeding	Contraindicated (Includes cerebrovascular bleeding)

Restricted/Not Recommended Use

Population/Condition	Restriction/Caution Status
Infants under 6 months or <5 kg	Use Not Established (Insufficient data)
Dehydration (especially in children)	Caution (Increased risk of renal impairment)
Uncontrolled Cardiovascular Conditions	Caution (e.g., severe hypertension, established ischaemic heart disease)

Medafen Paediatric should be used with caution in children who have a history of certain gastrointestinal diseases, such as Crohn's disease or ulcerative colitis, as their condition may be worsened. Always consult a healthcare professional regarding eligibility, especially for children with pre-existing chronic conditions.

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for the active ingredient, Ibuprofen, as established by governmental regulatory agencies.

Official Interaction Statements

Medafen Paediatric must be avoided or used with specific constraints when co-administered with certain medicinal products, foods, or substances.

• Contraindicated Combinations: Co-administration with other non-aspirin NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), including COX-2 selective inhibitors, is officially restricted due to a heightened risk of serious adverse effects, such as gastrointestinal bleeding and ulceration.
• Pharmacokinetic Exposure Modification: Regulatory documents state that Ibuprofen may reduce the renal clearance of substances like Lithium and Methotrexate, which can lead to increased plasma concentrations and potential toxicity of those co-administered drugs.
• Pharmacodynamic Risk Enhancement: Concomitant use with Anticoagulants (e.g., Warfarin), Oral Corticosteroids, and SSRIs is documented to enhance the risk of bleeding and haemorrhage due to additive pharmacodynamic effects.
• Reduction of Efficacy: Ibuprofen may diminish the desired effect of most Diuretics and Antihypertensive medications, including ACE inhibitors and ARBs.
• Timing Requirement: A formal timing rule specifies that Ibuprofen must be administered at least two hours before the dose of low-dose Aspirin to minimize interference with its antiplatelet action.
• Substance Interactions: The consumption of Alcohol is officially noted to increase the risk of serious gastrointestinal bleeding when combined with Ibuprofen.

Interaction Context Constraints

These constraints include cautions for specific populations, where the interaction leading to a deterioration of renal function with certain antihypertensives is officially heightened for patients who are volume-depleted or who have existing renal or hepatic impairment.

Enzymatic Inhibition of Prostaglandin Synthesis

The active ingredient, Ibuprofen, is a non-selective, competitive, reversible inhibitor of the Cyclooxygenase (COX) enzyme system, targeting both COX-1 and COX-2 isoforms. This molecular interaction blocks the enzymatic conversion of arachidonic acid, which is the essential initial step for the creation of prostaglandins and other eicosanoids, which are signaling molecules whose concentration is elevated in specific biological responses.

Modulation of Central and Peripheral Signaling

The resultant suppression of prostaglandin synthesis affects the body at a system level. By modulating prostaglandin levels in the hypothalamus, the drug supports a lowering of the thermal set point. Concurrently, suppression in peripheral nerves modifies the early molecular steps that limit the sensitization threshold of nociceptive fibers.

Attenuation of Nociceptor Excitability

This mechanism acts to attenuate the local generation of inflammatory mediators. Limiting the synthesis of mediators at the tissue level decreases the peripheral concentration of molecules that amplify nociceptive signals and mediate local vascular permeability, defining the drug's core functional outcome.

Medafen Paediatric is an oral suspension and is administered exclusively by mouth for systemic effect. The use of this medicine is structured by specific rules regarding dose calculation, administration technique, frequency, and duration.

Administration Scope

Usage Parameter	General parameters
Route of administration	Oral administration of the liquid suspension.
Dosing schedule	Dosage is primarily determined by the child's weight, or age if weight is unknown. The typical maximum daily dose is 40 mg/kg in divided doses for pediatric prescription use.
Frequency and Interval	A dose may be repeated every 6 to 8 hours if needed. A minimum interval of at least 4 hours must be maintained between doses, and no more than 4 doses should be given in 24 hours.
Age-group rules	The medicine is typically for use in infants beginning at 3 months of age, provided the child weighs more than 5 kg.

Procedural Structure and Conditions

The following guidelines emphasize preparation and precise measurement for proper use:

• Preparation Requirements: The bottle must be shaken well before each use to ensure consistency in the liquid suspension.
• Measuring the Dose: Administration must be performed using only the provided dosing device (cup or syringe) to guarantee the accurate volume is measured.
• Timing with Food: The medicine may be taken with food or milk to help alleviate potential stomach upset.
• Duration Limit: The medicine is for short-term use only. If symptoms persist or worsen, or if the medicine is required for more than 3 days (for fever) or 10 days (for pain), medical consultation is advised.

This protocol defines the standardized approach for using the medicine, ensuring that the appropriate amount is given at the correct time intervals and for the intended limited duration.

Recent Clinical Evidence

Clinical research on Medafen Paediatric (ibuprofen) primarily focuses on its use as an analgesic (pain reliever) and antipyretic (fever reducer) in children. Studies confirm its established profile for the short-term symptomatic management of mild to moderate pain and fever.

Efficacy for Fever and Pain Relief

A systematic review published in 2020 compared the use of ibuprofen to acetaminophen for fever and pain in children younger than two years. Findings suggested that ibuprofen was associated with a higher likelihood of children being afebrile (fever-free) at four and 24 hours after treatment compared to acetaminophen. Studies also reported that ibuprofen was associated with reduced pain at four to 24 hours post-treatment, supporting its use for conditions like musculoskeletal injuries and dental pain.

Comparative Safety and Tolerability

Regulatory and post-marketing data indicate that ibuprofen has a well-established short-term safety profile when used appropriately. Safety comparisons in randomized controlled trials (RCTs) generally suggest similar rates of serious adverse events between ibuprofen and acetaminophen in the short term. The most commonly reported side effects across trials are minor and affect the gastrointestinal (GI) tract.

Focus of Study	Key Finding (Neutral Summary)
Fever Reduction	Associated with a higher rate of children becoming afebrile compared to acetaminophen in the short-term.
Pain Relief	Showed reduced pain in children with musculoskeletal and other acute injuries over four to 24 hours.

Clinical Considerations and Limitations

While evidence supports its short-term use, caution is recommended in specific pediatric groups, such as children with a risk of dehydration or certain underlying medical conditions, due to the potential for adverse effects on kidney function. Research emphasizes the necessity of using appropriate weight-based dosing and maintaining patient hydration to minimize risk. Long-term safety data remains limited, and ongoing research continues to refine its therapeutic applications.

Common questions about Medafen Paediatric (FAQ)

---

Q: What should I do if I forget a dose?

The official product information provides guidance on how to manage a forgotten dose. Generally, if it is remembered soon after the missed time, it may be taken. However, if it is almost time for the next scheduled dose, it is typically recommended to skip the missed dose and continue with the regular schedule. Specific details are outlined in the official package leaflet or prescribing information.

---

Q: Can I drink alcohol while taking Medafen Paediatric?

Official regulatory warnings indicate that the use of alcohol should be avoided while using Medafen Paediatric. This is because combining the medication with alcohol may increase the risk of experiencing certain side effects. Complete details are available within the warnings section of the official product information.

---

Q: Can children 2 years old use Medafen Paediatric?

According to the official prescribing information, Medafen Paediatric is specifically indicated for use in patients aged 12 years and older. It is not indicated for use in children who are 2 years old.

---

Q: How long is it safe to take Medafen Paediatric?

The product's regulatory documents specify the maximum recommended duration for taking this medicine. This information is typically found in the Indications and Dosage section. The maximum duration of use specified in the product information should not be exceeded.

---

Q: Does Medafen Paediatric cause weight gain?

Official regulatory records, which include clinical study data, indicate that weight gain has been reported as an adverse reaction associated with this medicine. Adverse reactions are effects observed during clinical trials or post-market experience. A complete list of reported side effects is documented in the official safety information section.

Storage and Disposal Requirements

Official regulatory documents define strict criteria for the storage and disposal of Medafen Paediatric suspension to maintain its integrity and ensure public safety.

Storage Conditions

Requirement	Official Statement
Temperature	Store at controlled room temperature (e.g., 20°C to 25°C). Do not freeze.
Protection	Keep the bottle tightly closed and store in a dry place, protected from excessive heat and moisture.
Child Safety	Always keep the medicine out of the sight and reach of children, ensuring the child-resistant cap is secured after each use.
Stability	Check the label for the specific in-use shelf-life (e.g., use within 6 months) after the bottle is opened.

Disposal Rules

Expired or unused medicine should be disposed of via an official drug take-back program. If a take-back program is unavailable, follow governmental guidance for disposal in household trash by mixing the liquid with an undesirable substance. The product must not be flushed down the toilet or poured down a drain.